scholarly journals BAY11‑7082 inhibits the expression of tissue factor and plasminogen activator inhibitor‑1 in type‑II alveolar epithelial cells following TNF‑α stimulation via the NF‑κB pathway

2020 ◽  
Vol 21 (2) ◽  
Author(s):  
Yumei Cheng ◽  
Bo Liu ◽  
Hong Qian ◽  
Huilin Yang ◽  
Yahui Wang ◽  
...  
Keyword(s):  
Epithelial Cells ◽  
Tissue Factor ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Alveolar Epithelial Cells ◽  
Type Ii ◽  
Plasminogen Activator Inhibitor 1 ◽  
Alveolar Epithelial ◽  
Tnf Α ◽  
Activator Inhibitor

Rat alveolar epithelial cells concomitantly express plasminogen activator inhibitor-1 and urokinase

1991 ◽  
Vol 260 (4) ◽  
pp. L286-L295 ◽  
Author(s):  
T. J. Gross ◽  
R. H. Simon ◽  
C. J. Kelly ◽  
R. G. Sitrin
Keyword(s):  
Epithelial Cells ◽  
Plasminogen Activator ◽  
Alveolar Epithelium ◽  
Plasminogen Activator Inhibitor ◽  
Alveolar Epithelial Cells ◽  
Plasminogen Activator Inhibitor 1 ◽  
Necrosis Factor Alpha ◽  
Alveolar Epithelial ◽  
Pai 1

There is considerable evidence to suggest that intra-alveolar plasminogen activation is instrumental in many aspects of inflammatory lung injury and subsequent tissue repair. Rat alveolar epithelial cells produce large quantities of urokinase-type plasminogen activator (uPA) in vitro, and uPA expression is modulated in association with cellular differentiation and exposure to inflammatory mediators. We now report that these cells also secrete heat-stable PA inhibitory activity having the characteristics of PA inhibitor type 1 (PAI-1). In particular, immunoreactive PAI-1 was demonstrable in conditioned media, cell lysates, and extracellular matrix from epithelial cell cultures. As alveolar epithelial cells differentiated in vitro, secreted PA inhibitor activity increased significantly from 104 +/- PAI U/ml (n = 5, mean +/- SE) on day 2 to 442 +/- 150 on day 7 in parallel with increases in secreted and matrix-associated immunoreactive PAI-1. PAI-1 mRNA expression decreased over this same period suggesting posttranscriptional regulation. The levels of both newly synthesized antigen and PAI-1 mRNA were increased by exposure to lipopolysaccharide and tumor necrosis factor-alpha. Thus, by the coexpression of uPA and PAI-1, the alveolar epithelium may actively regulate the generation of plasmin in both the normal and injured alveolus.

scholarly journals Plasminogen activator inhibitor-1 is increased in colonic epithelial cells from patients with colitis-associated cancer

2013 ◽  
Vol 7 (5) ◽  
pp. 403-411 ◽  
Author(s):  
Earl Gillespie ◽  
Susan E. Leeman ◽  
Luisa A. Watts ◽  
Jennifer A. Coukos ◽  
Michael J. O'Brien ◽  
...  
Keyword(s):  
Epithelial Cells ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Plasminogen Activator Inhibitor 1 ◽  
Colonic Epithelial Cells ◽  
Activator Inhibitor

Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-α?

1999 ◽  
Vol 143 (1) ◽  
pp. 81-90 ◽  
Author(s):  
M. Cigolini ◽  
M. Tonoli ◽  
L. Borgato ◽  
L. Frigotto ◽  
F. Manzato ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Human Adipose Tissue ◽  
Plasminogen Activator Inhibitor 1 ◽  
Tnf Α ◽  
Activator Inhibitor

gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex

1995 ◽  
Vol 108 (6) ◽  
pp. 2361-2368 ◽  
Author(s):  
S. Stefansson ◽  
M.Z. Kounnas ◽  
J. Henkin ◽  
R.K. Mallampalli ◽  
D.A. Chappell ◽  
...  
Keyword(s):  
Ligand Binding ◽  
Plasminogen Activator ◽  
Solid Phase ◽  
Polyclonal Antibodies ◽  
Plasminogen Activator Inhibitor ◽  
Type Ii ◽  
Plasminogen Activator Inhibitor 1 ◽  
Type Ii Pneumocytes ◽  
Activator Inhibitor ◽  
Pai 1

Glycoprotein 330 (gp330) is a member of a family of receptors related to the low density lipoprotein receptor (LDLR). Although several ligands have been shown to bind gp330 in solid-phase assays, the ability of gp330 to mediate ligand endocytosis has not been demonstrated. To develop a cellular model for gp330 function we screened a variety of cultured cell lines and identified several that expressed this protein, including immortalized rat type II pneumocytes and a human and two rodent tumor cell lines. Using type II pneumocytes, endocytosis of a previously described gp330 ligand, urokinase (uPA) complexed with plasminogen activator inhibitor-1 (uPA:PAI-1) and two new ligands, PAI-1 and pro-uPA, was demonstrated. RAP, the 39 kDa receptor-associated protein known to antagonize ligand binding to gp330 in solid-phase binding assays, completely inhibited both internalization and degradation of the radiolabeled ligands by type II pneumocytes. This suggested that the clearance of these ligands was dependent on either gp330 or the LDLR-related protein (LRP), which shares several ligand-binding characteristics with gp330. By using polyclonal antibodies to gp330, the cellular internalization and degradation of the ligands were inhibited by 30–50%; remaining ligand internalization and degradation activity could be partially inhibited by polyclonal antibodies against LRP. These findings indicate that gp330, like other LDLR family members, mediates endocytosis of its ligands. In addition, gp330 acts in concert with LRP in type II pneumocytes to mediate clearance of a variety of proteins involved in plasminogen activation, including uPA:PAI-1 complexes PAI-1 and pro-uPA.(ABSTRACT TRUNCATED AT 250 WORDS)

scholarly journals Plasminogen activator inhibitor-1 inhibits factor VIIa bound to tissue factor

2011 ◽  
Vol 9 (3) ◽  
pp. 531-539 ◽  
Author(s):  
P. SEN ◽  
A. A. KOMISSAROV ◽  
G. FLOROVA ◽  
S. IDELL ◽  
U. R. PENDURTHI ◽  
...  
Keyword(s):  
Tissue Factor ◽  
Plasminogen Activator ◽  
Factor Viia ◽  
Plasminogen Activator Inhibitor ◽  
Plasminogen Activator Inhibitor 1 ◽  
Activator Inhibitor
Sign in / Sign up

Export Citation Format

Share Document